Clinical trial · Interventional

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled ：A Randomized, Parallel Controlled Trial

NCT05848635CI-TRIAL-00066231unknownPhase 4ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This randomized, parallel controlled, single blind trial is designed to evaluate the efficacy and safety of hydromorphone versus morphine for perioperative analgesia in lung tumor ablation.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Ablation	—	UNRESOLVED	—
Pulmonary Nodule	—	UNRESOLVED	—

Interventions

Interventions (2)

Intervention	Type	Mapped drug	Match
Hydromorphone Hydrochloride	Drug	—	UNRESOLVED
Morphine hydrochloride	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (2)

type
EXPERIMENTAL
label
Experimental: Lung tumor ablation using hydromorphone for pain control and anaesthesia
description
Premedication:hydromorphone is started 15min before surgery with a single subcutaneous injection of 2mg. Intraoperative administration:NRS（Numeric Rating Scale）≥7 during operation, 2mg hydromorphone is injected intravenously and slowly pushed for 2-3 minutes. Postoperative administration:The drug is administered as needed according to the patient's postoperative pain, 2mg/time.
interventionNames
1. Drug: Hydromorphone Hydrochloride
type
ACTIVE_COMPARATOR
label
Active Comparator:Lung tumor ablation using morphine for pain control and anaesthesia
description
Premedication:morphine is started 15min before surgery with a single subcutaneous injection of 10mg. Intraoperative administration:NRS（Numeric Rating Scale）≥7 during operation, 10mg morphine is injected intravenously and slowly pushed for 2-3 minutes. Postoperative administration:The drug is administered as needed according to the patient's postoperative pain, 10mg/time.
interventionNames

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 80 Years

Show eligibility criteria text

Inclusion Criteria:

* Voluntarily attend and sign the informed consent form in person;
* Patients undergoing selective pulmonary tumor ablation;
* The Eastern Collaborative Oncology Group (ECOG) defines an activity status score of 2 or less;
* The estimated survival time is more than 3 months;
* Age 18-80, both sexes.

Exclusion Criteria:

* Severe coagulation dysfunction that cannot be corrected;
* History of severe cardio-cerebrovascular and respiratory diseases;
* Patients allergic to test drugs or contrast media;
* Patients with opioid addiction;
* Patients with cognitive dysfunction;
* Participated in other clinical investigators within three months;
* Investigators or their family members directly involved in the trial;
* Those who are deemed unfit to participate in the study by the investigator.

References

Publications (0)

Data not yet available

No reference posted for this study.